APC 366

Drug Profile

APC 366

Alternative Names: APC 366-A; APC 366-C; APC 366-R

Latest Information Update: 15 Oct 1998

Price : $50

At a glance

  • Originator Celera Genomics Group
  • Class Antiasthmatics; Antithrombotics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Mast cell tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 15 Oct 1998 Discontinued-II for Asthma in United Kingdom (Inhalation)
  • 15 Oct 1998 Discontinued-II for Asthma in USA (Inhalation)
  • 17 Sep 1998 Axys Pharmaceuticals has filed an IND for a dry powder inhaler formulation of APC 366
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top